TABLE 4.
Summary of response rate per Lugano 2014 criteria, all‐treated population
| Cohort A1: cHL (anti‐PD‐1/PD‐L1 naïve) (n = 18) | Cohort A2: cHL (anti‐PD‐1/PD‐L1 progressors) (n = 12) | Cohort B: DLBCL (n = 17) | Cohort C: PTCL (n = 11) | |
|---|---|---|---|---|
| Overall response | ||||
| Responders (CR or PR) | 10 (55.6) | 4 (33.3) | 1 (5.9) | 1 (9.1) |
| Best overall response | ||||
| Complete metabolic response/complete response | 5 (27.8) | 2 (16.7) | 1 (5.9) | 0 |
| Partial metabolic response/partial response | 5 (27.8) | 2 (16.7) | 0 | 1 (9.1) |
| No metabolic response/stable disease | 1 (5.6) | 3 (25.0) | 0 | 1 (9.1) |
| Progressive metabolic disease/progressive disease | 6 (33.3) | 5 (41.7) | 7 (41.2) | 4 (36.4) |
| Not evaluable a | 1 (5.6) | 0 | 9 (52.9) | 5 (45.5) |
Note: All data are shown as n (%).
Abbreviations: cHL, classic Hodgkin's lymphoma; CR, complete response; DLBCL, diffuse large B‐cell lymphoma; PD‐1, programmed death‐1; PD‐L1, programmed death ligand‐1; PR, partial response; PTCL, peripheral T‐cell lymphoma.
a
Including patients with no post‐baseline evaluation prior to the initiation of a new anti‐cancer therapy or the data cutoff date.